학술논문
Continuous positive airway pressure for prevention of cardiovascular events and mortality: why evidence is evolving.
Document Type
Editorial & Opinion
Author
Pépin JL; University Grenoble Alpes, HP2 Laboratory, INSERM U1300, Grenoble, France jpepin@chu-grenoble.fr.; EFCR Laboratory, Grenoble Alpes University Hospital, Grenoble, France.; Randerath W; Bethanien Hospital, Clinic for Pneumology and Allergology, Centre of Sleep Medicine and Respiratory Care, Institute of Pneumology at the University of Cologne, Solingen, Germany.
Source
Publisher: European Respiratory Society Country of Publication: England NLM ID: 8803460 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1399-3003 (Electronic) Linking ISSN: 09031936 NLM ISO Abbreviation: Eur Respir J Subsets: MEDLINE
Subject
Language
English
Abstract
Competing Interests: Conflict of interest: J-L. Pépin is supported by the French National Research Agency in the framework of the “Investissements d’avenir” programme (ANR-15-IDEX-02) and the “e-health and integrated care and trajectories medicine and MIAI artificial intelligence” chairs of excellence from the Grenoble Alpes University Foundation; this work has been partially supported by MIAI @ university Grenoble Alpes (ANR-19-P3IA-0003); J-L. Pépin has received lecture fees or conference travel grants from ResMed, Philips, AstraZeneca, Jazz Pharmaceuticals, Agiradom and Bioprojet, and has received unrestricted research funding from ResMed, Philips, GlaxoSmithKline, Bioprojet, Fondation de la Recherche Medicale (Foundation for Medical Research), Direction de la Recherche Clinique du CHU de Grenoble (Research Branch Clinic CHU de Grenoble), and fond de dotation “Agir pour les Maladies Chroniques” (endowment fund “Acting for Chronic Diseases”). W. Randerath reports participation on an advisory board for Bioprojet and Procter & Gamble (consultancy), speaking fees and travel grants from Bioprojet, Heinen & Löwenstein, Habel Medizintechnik, Jazz Pharmaceutical, Philips Respironics and Westfalen Medical.